You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTiaprofenic acid
Accession NumberDB01600
TypeSmall Molecule
GroupsApproved
DescriptionTiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain.
Structure
Thumb
Synonyms
2-(5-Benzoyl-thiophen-2-yl)-propionic acid
2-(5-Benzyl-2-thienyl)propionsaeure
5-Benzoyl-alpha-methyl-2-thiopheneacetic acid
5-Benzoyl-alpha-methylthiophene-2-acetic acid
Acide tiaprofenique
Acido tiaprofenico
Acidum tiaprofenicum
alpha-Methyl-5-benzoyl-2-thienylacetic acid
Tiaprofensaeure
Tiaprofensäure
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Albert Tiafen SRCapsule, extended release300 mgOralAventis Pharma IncNot applicableNot applicableCanada
Albert Tiafen Tab 200mgTablet200 mgOralAventis Pharma Inc1991-12-312004-07-30Canada
Albert Tiafen Tab 300mgTablet300 mgOralAventis Pharma Inc1991-12-312004-07-30Canada
Dom-tiaprofenicTablet300 mgOralDominion Pharmacal2000-06-20Not applicableCanada
Dom-tiaprofenicTablet200 mgOralDominion PharmacalNot applicableNot applicableCanada
Nu-tiaprofenic - Tab 200mgTablet200 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Nu-tiaprofenic - Tab 300mgTablet300 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Penta-tiaprofenic TabletsTablet300 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-tiaprofenic TabletsTablet200 mgOralPentapharm Ltd.Not applicableNot applicableCanada
PMS-tiaprofenicTablet200 mgOralPharmascience Inc1999-01-24Not applicableCanada
PMS-tiaprofenicTablet300 mgOralPharmascience Inc1997-07-08Not applicableCanada
SurgamTablet300 mgOralSanofi Aventis Canada Inc1997-08-202007-11-22Canada
Surgam SRCapsule, extended release300 mgOralSanofi Aventis Canada Inc1997-02-212007-07-31Canada
Surgam SR Cap 300mgCapsule, extended release300 mgOralHoechst Roussel Canada Inc.1990-12-311999-08-11Canada
Surgam Tab 200mgTablet200 mgOralRoussel Canada Inc.1986-12-311997-08-05Canada
Surgam Tab 200mgTablet200 mgOralHoechst Roussel Canada Inc.1996-12-312001-07-20Canada
Surgam Tab 300mgTablet300 mgOralHoechst Roussel Canada Inc.1995-12-311999-08-11Canada
Surgam Tab 300mgTablet300 mgOralRoussel Canada Inc.1986-12-311997-08-05Canada
Surgam-SR Src 300mgCapsule, extended release300 mgOralRoussel Canada Inc.1990-12-311996-09-09Canada
Teva-tiaprofenic AcidTablet200 mgOralTeva Canada Limited1996-12-31Not applicableCanada
Teva-tiaprofenic AcidTablet300 mgOralTeva Canada Limited1996-12-31Not applicableCanada
Tiaprofenic-200 - TabTablet200 mgOralPro Doc Limitee1996-12-312009-07-23Canada
Tiaprofenic-300 - TabTablet300 mgOralPro Doc Limitee1996-12-312009-07-23Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tiaprofenic Tablets -300mgTablet300 mgOralApotex Inc1994-12-31Not applicableCanada
Apo-tiaprofenic Tablets-200mgTablet200 mgOralApotex Inc1994-12-31Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SurgamylNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII1LS1T6R34C
CAS number33005-95-7
WeightAverage: 260.308
Monoisotopic: 260.05071494
Chemical FormulaC14H12O3S
InChI KeyGUHPRPJDBZHYCJ-UHFFFAOYSA-N
InChI
InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)
IUPAC Name
2-(5-benzoylthiophen-2-yl)propanoic acid
SMILES
CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1
Pharmacology
IndicationTiaprofenic acid is used to treat pain, especially arthritic pain.
Structured Indications
PharmacodynamicsTiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain. The typical adult dose is 300mg twice daily. It is not recommended in children.
Mechanism of actionTiaprofenic acid belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It works by blocking the production of a chemical (prostaglandin) which the body produces in response to injury or certain diseases. This prostaglandin would otherwise go on to cause swelling, pain and inflammation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinyes
inhibitor
HumanP23219 details
Related Articles
AbsorptionBioavailability is 90% following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic (10%). Sparingly metabolised in the liver to two inactive metabolites.

Route of eliminationNot Available
Half life1.5-2.5 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Tiaprofenic Acid Action PathwayDrug actionSMP00705
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabTiaprofenic acid may increase the anticoagulant activities of Abciximab.Approved
AcebutololTiaprofenic acid may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Aceclofenac.Approved
AcenocoumarolTiaprofenic acid may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tiaprofenic acid.Approved, Vet Approved
AclarubicinTiaprofenic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tiaprofenic acid.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alendronic acid.Approved
AliskirenTiaprofenic acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololTiaprofenic acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Amcinonide.Approved
AmikacinTiaprofenic acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideTiaprofenic acid may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinTiaprofenic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodTiaprofenic acid may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Anisodamine.Investigational
annamycinTiaprofenic acid may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tiaprofenic acid.Approved
Antithrombin III humanTiaprofenic acid may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Tiaprofenic acid may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanTiaprofenic acid may increase the anticoagulant activities of Apixaban.Approved
ApramycinTiaprofenic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Apremilast.Approved, Investigational
ArbekacinTiaprofenic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinTiaprofenic acid may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanTiaprofenic acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololTiaprofenic acid may decrease the antihypertensive activities of Arotinolol.Approved
AtenololTiaprofenic acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tiaprofenic acid.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tiaprofenic acid.Approved
BalsalazideTiaprofenic acid may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminTiaprofenic acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTiaprofenic acid may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tiaprofenic acid.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tiaprofenic acid.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tiaprofenic acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Betamethasone.Approved, Vet Approved
BetaxololTiaprofenic acid may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Betulinic Acid.Investigational
BevantololTiaprofenic acid may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
BisoprololTiaprofenic acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTiaprofenic acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTiaprofenic acid may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tiaprofenic acid.Approved
BucillamineThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Bucillamine.Investigational
BucindololTiaprofenic acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Budesonide.Approved
BufuralolTiaprofenic acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideTiaprofenic acid may decrease the diuretic activities of Bumetanide.Approved
BupranololTiaprofenic acid may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tiaprofenic acid.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tiaprofenic acid.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Tiaprofenic acid.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tiaprofenic acid.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Tiaprofenic acid.Approved, Vet Approved, Withdrawn
CarteololTiaprofenic acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolTiaprofenic acid may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Celecoxib.Approved, Investigational
CeliprololTiaprofenic acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinTiaprofenic acid may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tiaprofenic acid.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tiaprofenic acid.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tiaprofenic acid.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tiaprofenic acid.Approved
CinoxacinTiaprofenic acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinTiaprofenic acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidTiaprofenic acid may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tiaprofenic acid.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Curcumin.Investigational
CyclosporineTiaprofenic acid may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with D-Limonene.Investigational
Dabigatran etexilateTiaprofenic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTiaprofenic acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTiaprofenic acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinTiaprofenic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinTiaprofenic acid may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tiaprofenic acid.Approved
DextranTiaprofenic acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Tiaprofenic acid may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Tiaprofenic acid may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Tiaprofenic acid may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tiaprofenic acid.Approved, Vet Approved
DicoumarolTiaprofenic acid may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tiaprofenic acid.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tiaprofenic acid.Approved
DihydrostreptomycinTiaprofenic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Tiaprofenic acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tiaprofenic acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tiaprofenic acid.Approved
DoxorubicinTiaprofenic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneTiaprofenic acid may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ebselen.Investigational
Edetic AcidTiaprofenic acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTiaprofenic acid may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tiaprofenic acid.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tiaprofenic acid.Approved
EnoxacinTiaprofenic acid may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinTiaprofenic acid may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Epirizole.Approved
EpirubicinTiaprofenic acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneTiaprofenic acid may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tiaprofenic acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tiaprofenic acid.Approved
EquileninThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Equilin.Approved
EsmololTiaprofenic acid may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Estrone sulfate.Approved
Etacrynic acidTiaprofenic acid may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tiaprofenic acid.Approved, Investigational
Ethyl biscoumacetateTiaprofenic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tiaprofenic acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Tiaprofenic acid.Vet Approved
FleroxacinTiaprofenic acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tiaprofenic acid.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fludrocortisone.Approved
FluindioneTiaprofenic acid may increase the anticoagulant activities of Fluindione.Investigational
FlumequineTiaprofenic acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Tiaprofenic acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tiaprofenic acid.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tiaprofenic acid.Approved, Nutraceutical, Vet Approved
FondaparinuxTiaprofenic acid may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTiaprofenic acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tiaprofenic acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tiaprofenic acid.Approved
FramycetinTiaprofenic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideTiaprofenic acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateTiaprofenic acid may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTiaprofenic acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTiaprofenic acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tiaprofenic acid.Approved, Withdrawn
GemifloxacinTiaprofenic acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTiaprofenic acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTiaprofenic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATiaprofenic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinTiaprofenic acid may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with HE3286.Investigational
HeparinTiaprofenic acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Higenamine.Investigational
HirulogTiaprofenic acid may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with HMPL-004.Investigational
HydralazineTiaprofenic acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tiaprofenic acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tiaprofenic acid.Approved
Hygromycin BTiaprofenic acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tiaprofenic acid.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Icatibant.Approved
IdarubicinTiaprofenic acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxTiaprofenic acid may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tiaprofenic acid.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tiaprofenic acid.Approved
IndenololTiaprofenic acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tiaprofenic acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Indoprofen.Withdrawn
INNO-206Tiaprofenic acid may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tiaprofenic acid.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Istaroxime.Investigational
KanamycinTiaprofenic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiaprofenic acid.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tiaprofenic acid.Approved
LabetalolTiaprofenic acid may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Tiaprofenic acid.Approved, Investigational
LepirudinTiaprofenic acid may increase the anticoagulant activities of Lepirudin.Approved
LevobunololTiaprofenic acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTiaprofenic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Tiaprofenic acid.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tiaprofenic acid.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Tiaprofenic acid.Approved
LomefloxacinTiaprofenic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tiaprofenic acid.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Tiaprofenic acid.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tiaprofenic acid.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tiaprofenic acid.Approved
ME-609The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiaprofenic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tiaprofenic acid.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tiaprofenic acid.Approved, Vet Approved
MesalazineTiaprofenic acid may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tiaprofenic acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tiaprofenic acid.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Methylprednisolone.Approved, Vet Approved
MetipranololTiaprofenic acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tiaprofenic acid.Approved
MetoprololTiaprofenic acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideTiaprofenic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tiaprofenic acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tiaprofenic acid.Approved
MometasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tiaprofenic acid.Approved
MoxifloxacinTiaprofenic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tiaprofenic acid.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiaprofenic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nabumetone.Approved
NadololTiaprofenic acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTiaprofenic acid may increase the anticoagulant activities of Nadroparin.Approved
NafamostatTiaprofenic acid may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tiaprofenic acid.Approved
Nalidixic AcidTiaprofenic acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Tiaprofenic acid.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with NCX 4016.Investigational
NeamineTiaprofenic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinTiaprofenic acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinTiaprofenic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nepafenac.Approved
NetilmicinTiaprofenic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nitroaspirin.Investigational
NorfloxacinTiaprofenic acid may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinTiaprofenic acid may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tiaprofenic acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiaprofenic acid.Approved
OlsalazineTiaprofenic acid may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Tiaprofenic acid.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Orgotein.Vet Approved
OtamixabanTiaprofenic acid may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tiaprofenic acid.Approved
OxprenololTiaprofenic acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Parecoxib.Approved
ParomomycinTiaprofenic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinTiaprofenic acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTiaprofenic acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTiaprofenic acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateTiaprofenic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Tiaprofenic acid.Approved
PhenindioneTiaprofenic acid may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonTiaprofenic acid may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tiaprofenic acid.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tiaprofenic acid.Approved, Investigational
PindololTiaprofenic acid may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinTiaprofenic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideTiaprofenic acid may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tiaprofenic acid.Approved, Investigational
PlicamycinTiaprofenic acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tiaprofenic acid.Approved
PorfimerTiaprofenic acid may increase the photosensitizing activities of Porfimer.Approved, Investigational
PractololTiaprofenic acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tiaprofenic acid.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Tiaprofenic acid can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Propacetamol.Approved
PropranololTiaprofenic acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Tiaprofenic acid.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Tiaprofenic acid.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Tiaprofenic acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Tiaprofenic acid.Vet Approved
Protein CTiaprofenic acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanTiaprofenic acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTiaprofenic acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTiaprofenic acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with PTC299.Investigational
PuromycinTiaprofenic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tiaprofenic acid.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tiaprofenic acid.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Tiaprofenic acid.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tiaprofenic acid.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Resveratrol.Experimental, Investigational
ReviparinTiaprofenic acid may increase the anticoagulant activities of Reviparin.Approved
RibostamycinTiaprofenic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Risedronate.Approved, Investigational
RivaroxabanTiaprofenic acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinTiaprofenic acid may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tiaprofenic acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tiaprofenic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Tiaprofenic acid.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tiaprofenic acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tiaprofenic acid.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Seratrodast.Approved, Investigational
SisomicinTiaprofenic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolTiaprofenic acid may decrease the antihypertensive activities of Sotalol.Approved
SP1049CTiaprofenic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinTiaprofenic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinTiaprofenic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Tiaprofenic acid.Approved
SpironolactoneTiaprofenic acid may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with SRT501.Investigational
StreptomycinTiaprofenic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinTiaprofenic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineTiaprofenic acid may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Tiaprofenic acid.Approved
SulodexideTiaprofenic acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Tiaprofenic acid.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Tiaprofenic acid.Approved, Withdrawn
TacrolimusTiaprofenic acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Tiaprofenic acid.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tiaprofenic acid.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tiaprofenic acid.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tiaprofenic acid.Approved, Investigational
TemafloxacinTiaprofenic acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Tiaprofenic acid.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tiaprofenic acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Teriflunomide.Approved
TiludronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tiludronate.Approved, Vet Approved
TimololTiaprofenic acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tixocortol.Approved
TobramycinTiaprofenic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tiaprofenic acid.Approved
TorasemideTiaprofenic acid may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tiaprofenic acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tiaprofenic acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTiaprofenic acid may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tiaprofenic acid.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tiaprofenic acid.Approved
TrovafloxacinTiaprofenic acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tiaprofenic acid.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinTiaprofenic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tiaprofenic acid.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tiaprofenic acid.Approved
VerteporfinTiaprofenic acid may increase the photosensitizing activities of Verteporfin.Approved, Investigational
WarfarinTiaprofenic acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTiaprofenic acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Tiaprofenic acid may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Tiaprofenic acid.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zomepirac.Withdrawn
ZorubicinTiaprofenic acid may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Avoid alcohol.
  • Take with food.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM01AE11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9927
Blood Brain Barrier+0.9289
Caco-2 permeable+0.6039
P-glycoprotein substrateNon-substrate0.7298
P-glycoprotein inhibitor INon-inhibitor0.9534
P-glycoprotein inhibitor IINon-inhibitor0.9664
Renal organic cation transporterNon-inhibitor0.8998
CYP450 2C9 substrateNon-substrate0.6293
CYP450 2D6 substrateNon-substrate0.9226
CYP450 3A4 substrateNon-substrate0.8098
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.8607
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.8958
CYP450 3A4 inhibitorNon-inhibitor0.9526
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.9398
CarcinogenicityNon-carcinogens0.7568
BiodegradationReady biodegradable0.7714
Rat acute toxicity3.1892 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9869
hERG inhibition (predictor II)Non-inhibitor0.9716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral300 mg
TabletOral200 mg
Capsule, extended releaseOral300 mg
Prices
Unit descriptionCostUnit
Apo-Tiaprofenic 300 mg Tablet0.43USD tablet
Novo-Tiaprofenic 300 mg Tablet0.43USD tablet
Nu-Tiaprofenic 300 mg Tablet0.43USD tablet
Apo-Tiaprofenic 200 mg Tablet0.36USD tablet
Novo-Tiaprofenic 200 mg Tablet0.36USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point96 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0324 mg/mLALOGPS
logP3.22ALOGPS
logP3.66ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)4.03ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity69.19 m3·mol-1ChemAxon
Polarizability26.78 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acetophenones. These are organic compounds containing the acetophenone structure.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAcetophenones
Direct ParentAcetophenones
Alternative Parents
Substituents
  • Acetophenone
  • Aryl ketone
  • Thiophene carboxylic acid or derivatives
  • Benzoyl
  • 2,5-disubstituted thiophene
  • Heteroaromatic compound
  • Thiophene
  • Ketone
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Brandt KD, Albrecht ME, Kalasinski LA: Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage. J Clin Pharmacol. 1990 Sep;30(9):808-14. [PubMed:2277128 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Patrignani P: Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res. 2003 Jun 15;110(5-6):281-6. [PubMed:14592549 ]
  2. Gupta K, Kaub CJ, Carey KN, Casillas EG, Selinsky BS, Loll PJ: Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors. Bioorg Med Chem Lett. 2004 Feb 9;14(3):667-71. [PubMed:14741265 ]
  3. Martic M, Tatic I, Markovic S, Kujundzic N, Kostrun S: Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors. Eur J Med Chem. 2004 Feb;39(2):141-51. [PubMed:14987823 ]
  4. Hillarp A: [Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism]. Lakartidningen. 2004 Nov 4;101(45):3504-6, 3508-9. [PubMed:15575422 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 12:44 / Updated on August 17, 2016 12:23